RGLaw secured a favorable result for its client for a patent application directed to Polyvalent Fusion Protein Vaccine Against Influenza. Upon receiving a Final Office Action, Roy Gross filed a Pre-Appeal Brief which successfully persuaded a three-person panel at the USPTO that the patent specification is enabling of the claims and that claimed invention is novel and non-obvious over the cited prior art. Issuance of a patent containing all pending claims is expected in due course
